Completed PHASE1 INTERVENTIONAL 2-arm NCT00653055

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

Randomized, 4-Way Replicate Crossover, Bioequivalence Study of Cabergoline 0.5 mg Tablets and Dostinex 0.5 mg Tablets Administered as 2 x 0.5 mg Tablets in Healthy Adult Females and Males Under Fasting Conditions

Sponsor: Anapharm

Conditions To Determine Bioequivalence Under Fasting Conditions

Interventions Cabergoline Dostinex

Updated 6 times since 2017 Last updated: Apr 3, 2008 Started: Aug 31, 2001 Primary completion: Dec 31, 2001 Completion: Dec 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates To Determine Bioequivalence Under Fasting Conditions and is currently completed. Anapharm leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anapharm
Par Pharmaceutical, Inc.

Data source: Par Pharmaceutical, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sainte-Foy, Canada